Last reviewed · How we verify
NCT05633420
Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
Phase 2 trial testing Pyramax in COVID-19 in 20 participants. Completed in 20 November 2022.
6 September 2022
Quick facts
| Lead sponsor | Shin Poong Pharmaceutical Co. Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 24 July 2022 |
| Primary completion | 6 September 2022 |
| Estimated completion | 20 November 2022 |
| Sites | 2 locations across South Korea |
Drugs / interventions tested
- Pyramax — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Shin Poong Pharmaceutical Co. Ltd. — full company profile →
Who can join
19 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multi-center, single-arm, open-label, pilot clinical trial to explore efficacy and safety of Pyramax in mild to moderate COVID-19 patients
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05633420
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pyramax
Trials testing the same drug.
- NCT05084911 — The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3) · Phase 3 · completed
- NCT04783051 — Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) · Phase 3 · completed
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Shin Poong Pharmaceutical Co. Ltd. trials
Trials by the same sponsor.
- NCT06660719 — Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of · Phase 3 · recruiting
- NCT07064525 — Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension · Phase 2 · enrolling by invitation
- NCT06826872 — Efficacy and Safety of SPC1001 in Patients With Essential Hypertension · Phase 2 · recruiting
- NCT06212648 — Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension · Phase 2 · completed
- NCT06225635 — A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05633420 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shin Poong Pharmaceutical Co. Ltd.
- Last refreshed: 2 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05633420.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing